Regulation and modulation of eosinophil effector functions

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 54, Issue 1, 1999, Pages 15-26

  Elsner, J ^a   Kapp, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allergy; Antagonist; Chemokine; Eosinophil

Indexed keywords

AUTACOID; CD69 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; COMPLEMENT COMPONENT C5A; CYTOKINE; EOTAXIN; HISTAMINE; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 5; MILODISTIM; MONOCLONAL ANTIBODY; THROMBOCYTE ACTIVATING FACTOR;

ALLERGY; APOPTOSIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; EFFECTOR CELL; EOSINOPHIL; HISTAMINE RELEASE; INFLAMMATION; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

EID: 0033053536     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/all.1999.54.1.15     Document Type: Review

References (168)

1. Kapp A. Atopic dermatitis - the skin manifestation of atopy. Clin Exp Allergy 1995;15:210-219.
2. Costa JJ, Weller PF, Galli SJ. The cells of the allergic response: mast cells, basophils, and eosinophils. JAMA 1997;278:1815-1822.
3. Erjefält JS, Korsgren M, Nilsson MC, Sundler F, Persson CG. Association between inflammation and epithelial damage-restitution processes in allergic airways in vivo. Clin Exp Allergy 1997;27:1344-1355.
4. Hogg JC. The pathology of asthma. APMIS 1997;105:735-745.
5. Klimek L, Eggers G. Olfactory dysfunction in allergic rhinitis is related to nasal eosinophilic inflammation. J Allergy Clin Immunol 1997;100:158-164.
6. 1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997;17:326-333.
7. Rowe-Jones JM, Smith NT, Shembekar M, Mackay IS. Polypoid rhinosinusitis in patients with host defence deficiencies: cellular infiltration and disease severity. Rhinology 1997;35:113-117.
8. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997;99:S763-72.
9. Bonini S, Magrini L, Rotiroti G, Lambiase A, Tomassini M, Rumi C. The eosinophil and the eye. Allergy 1997;52:44-47.
10. Bachert C, Wagenmann M, Holtappels G. Cytokines and adhesion molecules in allergic rhinitis. Am J Rhinol 1998;12:3-8.
11. Aractingi S, Janin A, Zini JM, et al. Specific mucosal erosions in hypercosinophilic syndrome: evidence for eosinophil protein deposition. Arch Dermatol 1996;132:535-541.
12. Czech W, Schaller J, Schöpf E, Kapp A. Granulocyte activation in bullous diseases - release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 1993;29:210-215.
13. Dhami D, Shutte JK. Mechanisms of epithelial damage: are there parallels between bullous skin diseases and asthma? Clin Exp Allergy 1994;24:1005.
14. Hansen ER. Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Arch Dermatol 1996;132:554-561.
15. Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opin Rheumatol 1997;9:562-570.
16. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:163-166.
17. Maggi E. The TH1/TH1 paradigm in allergy. Immunotechnology 1998;3:233-234.
18. Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1993;175:1285-1290.
19. Rochester CL, Ackermann SJ, Zheng T, Elias JA. Eosinophil-fibroblast interactions - granule major basic protein interacts with IL-i and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J Immunol 1996;156:4449-4456.
20. Rosenberg HF, Tiffany HL. Characterization of the eosinophil granule proteins recognized by the activation-specific antibody EG2. J Leukoc Biol 1994;56:502-506.
21. Schröder JM, Noso N, Sticherling M, Christophers E. Role of eosinophilchemotactic C-C chemokines in cutaneous inflammation. J Leukoc Biol 1996;59:1-5.
22. Takafuji S, Ohtoshi T, Takizawa H, Tadokoro K, Ito K. Eosinophil degranulation in the presence of bronchial epithelial cells - effect of cytokines and role of adhesion. J Immunol 1996;156:3980-3985.
23. Ying S, Taborda Barata L, Meng Q, Humbert M, Kay AB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181:2153-2159.
24. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma. Clin Exp Allergy 1998;28:233-240.
25. Baggiolini M, Dewald B, Moser B. Human chemokincs: an update. Annu Rev Immunol 1997;15:675-705.
26. Elsner J, Oppermann M, Czech W, et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518-522.
27. Kapp A, Zeck Kapp G, Czech W, Schöpf E. The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J Invest Dermatol 1994;102:906-914.
28. Zeck Kapp G, Kroegel C, Riede UN, Kapp A. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy 1995;50:34-47.
29. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of cotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant colocalization of cotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507-3516.
30. del Pozo MA, Sanchez-Mateos P, Sanchez-Madrid F. Cellular polarization induced by chemokines: a mechanism for leukocyte recruitment. Immunol Today 1996;17:127-131.
31. Kitayama J, Mackay CR, Ponath PD, Springer TA. The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow. J Clin Invest 1998;101:2017-2024.
32. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84:359-369.
33. Mitchison TJ, Cramer LP. Actin-based cell motility and cell locomotion. Cell 1996;84:371-379.
34. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
35. Elsner J, Hochstetter R, Kimmig D, Kapp A. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 1996;26:1919-1925.
36. 35a. Eisner J, Dichmann S, Dobos G, Kapp A. Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization. J Cell Physiol 1996;167:548-555.
37. Coyle AJ, Ackermann S, Burch R, Proud D, Irvin CG. Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest 1995;95:1735-1740.
38. Elsner J, Dichmann S, Kapp A. Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. J Invest Dermatol 1995;105:231-236.
39. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis - eosinophil granule proteins as markers of disease activity. Allergy 1993;48:1-5.
40. Lundqvist H, Follin P, Khalfan L, Dahlgren C. Phorbol myristate acetate-induced NADPH oxidasc activity in human neutrophils: only half the story has been told. J Leukoc Biol 1996;59:270-279.
41. Remick DG, Villarete L. Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. J Leukoc Biol 1996;59:471-475.
42. Polentarutti N, Introna M, Sozzani S, Mancinelli R, Mantovani G, Mantovani A. Expression of monocyte chemotactic protein-3 in human monocytes and endothelial cells. Eur Cytokine Netw 1997;8:271-274.
43. Los M, Schenk H, Hexel K, et al. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995;14:3731-3740.
44. Los M, Droge W, Stricker K, Baeuerle PA, Schulze Osthoff K. Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur J Immunol 1995;25:159-165.
45. 2+ and reactive oxygen intermediates as messengers. FEBS Lett 1996;392:129-136.
46. 2+ influx, actin polymerization and release of eosinophil cationic protein of an eosinophilic leukaemia cell line EoL-1. Curr Med Res Opin 1993;13:163-174.
47. Czech W, Krutmann J, Budnik A, Schöpf E, Kapp A. Induction of intercellular adhesion molecule 1 (ICAM-1) expression in normal human eosinophils by inflammatory cytokines. J Invest Dermatol 1993;100:417-423.
48. Nagata M, Sedgwick JB, Bates ME, Kita H, Busse WW. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol 1995;155:2194-2202.
49. Nakayama H, Sano H, Nishimura T, Yoshidi S, Iwamoto I. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/ lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 1994;179:1145-1154.
50. Schleimer RP, Sterbinsky SA, Kaiser J, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992;148:1086-1092.
51. Symon FA, Walsh CM, Watson SR, Wardlaw AJ. Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent. J Exp Med 1994;180:371-376.
52. Walsh GM, Mermod JJ, Hartnell A, Kay AB, Wardlaw AJ. Human eosinophil, but not ncutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol 1991;146:3419-3423.
53. εRII) - comparison with B cell CD23 and association with an adhesion molecule. J Immunol 1989;143:3580-3588.
54. Monteiro RC, Hostoffer RW, Cooper MD, Bonner JR, Gartland GL, Kubagawa H. Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 1993;92:1681-1685.
55. Koenderman L, Hermans SW, Capel PJ, van de Winkel JG. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. Blood 1993;81:2413-2419.
56. Clark-Lewis I, Kim KS, Rajarathnam K, et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995;57:703-711.
57. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 1995;270:16491-4.
58. Gao JL, Kuhns DB, Tiffany HL, et al. Structure and functional expression of the human macrophage inflammatory 1a/ RANTES receptor. J Exp Med 1993;177: 1421-1427.
59. Kitaura M, Nakajima T, Imai T, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996;271:7725-7730.
60. Neote K, DiGregorio D, Mak JY, Horuk R, Schall TJ. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993;72:415-425.
61. Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88:4684-4693.
62. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993;80:281-286.
63. Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol 1992;90:169-174.
64. Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC, Jr, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol 1996;157:1678-1683.
65. Walsh CM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ. Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocytemacrophage colony-stimulating factor. Blood 1996;87:2815-2821.
66. Capron A, Capron M, Grangette C, Dessaint JP. IgE and inflammatory cells. Ciba Found Symp 1989;147:153-170.
67. Capron M, Truong MJ, Aldebert D, et al. Heterogeneous expression of CD23 epitopes by eosinophils from patients. Relationships with IgE-mediated functions. Eur J Immunol 1991;21:2423-2429.
68. Gounni AS, Lamkhioued B, Delaporte E, et al. The high-affinity IgE receptor on eosinophils: from allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 1994;94:1214-1216.
69. Gounni AS, Lamkhioued B, Ochiai K, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-186.
70. Metzger H. The receptor with high affinity for IgE. Immunol Rev 1992;125:37-48.
71. Terada N, Konno A, Terada Y, et al. IL-4 upregulates FctRI a-chain messenger RNA in eosinophils. J Allergy Clin Immunol 1995;96:1161-1169.
72. Gauchat JF, Henchoz S, Fattah D, et al. CD4o ligand is functionally expressed on human eosinophils. Eur J Immunol 1995;25:863-865.
73. Ohkawara Y, Lim KG, Xing Z, et al. CD4o expression by human peripheral blood eosinophils. J Clin Invest 1996;97:1761-1766.
74. Femvik E, Hallden G, Hed J, Lundahl J. Intracellular and surface distribution of CD9 in human eosinophils. APMIS 1995;103:699-706.
75. Hale G, Xia MQ, Tighe HP, Dyer MJS, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127.
76. Treumann A, Lifely RM, Schneider P, Ferguson MAJ. Primary structure of CD52. J Biol Chem 1995;270:6088-6099.
77. Xia MQ, Tone M, Packman L, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Imnnmol 1991;21:1677-1684.
78. Hugh TE. Structure and function of 033 anaphylatoxins. Curr Top Microbiol Immunol 1989;153:181-208.
79. Takabayashi T, Vannier E, Clark BD, et al. A new biologic role of C3a and C3a desArg - regulation of TNF-α and IL-1β synthesis. J Immunol 1996;156:3455-3460.
80. Martin U, Bock D, Arseniev L, et al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med 1997;186:199-207.
81. Zwirner f, Götze O, Moser A, et al. Blood-and skin-derived monocytes/macrophages respond to C3a but not to C3a (desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway. Eur J Immunol 1997;27:2317-2322.
82. Nagata S, Glovsky MM, Kunkel SL. Anaphylatoxin-induced neutrophil chemotaxis and aggregation. Int Arch Allergy Appl Immunol 1987;82:4-9.
83. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-2127.
84. Elsner J, Oppermann M, Czech W, Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 1994;83:3324-3331.
85. Oppermann M, Goïtze O. Plasma clearance of the human Csa anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994;82:516-521.
86. Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Götze O. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992;79:152-160.
87. Morgan EL, Ember JA, Sanderson SD, et al. Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derives from the predicted amino-terminal sequence of the human C5a receptor. J Immunol 1993;151:377-388.
88. 2-terminal domain. J Immunol 1993;151:49-55.
89. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614-617.
90. Gerard NP, Hodges MK, Drazen JM, Weiler PF, Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem 1989;264:1760-1766.
91. Weller PF. The immunobiology of eosinophils. N Engl J Med 1991;324:1110-1118.
92. Zeck Kapp G, Czech W, Kapp A. TNF alpha-induced activation of eosinophil oxidative metabolism and morphology - comparison with IL-5. Exp Dermatol 1994;3:176-188.
93. Kay AB, Barata L, Meng Q, Durham SR, Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation, Int Arch Allergy Immunol 1997;113:196-199.
94. Karlen S, De Boer ML, Lipscombe RJ, Lutz W, Mordvinov VA, Sanderson CJ. Biological and molecular characteristics of interleukin-5 and its receptor. Int Rev Immunol 1998;16:227-247.
95. Schwenk U, Schröder JM. 5-Oxo-eicosanoids are potent eosinophil chemotactic factors: functional characterization and structural requirements. J Biol Chem 1995;270:15029-15036.
96. Schwenk U, Morita E, Engel R, Schröder JM. Identification of 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid as a novel and potent human eosinophil chemotactic eicosanoid. J Biol Chem 1992;267:12482-12488.
97. Yoshie O, Imai T, Nomiyama H. Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 1997;62:634-644.
98. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-644.
99. Luster AD, Rothenberg ME. Role of the monocyte chemoattractant protein and cotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol 1997;62:620-633.
100. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
101. Moser B, Loetscher M, Piali L, Loetscher P. Lymphocyte responses to chemokines. Int Rev Immunol 1998;16:323-344.
102. Baggiolini M, Walz A, Kunkel SL. Neutrophil activating peptide-1/ interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-1049.
103. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994;94:1012-1018.
104. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 1990;171:1792-1802.
105. 2-terminal amino acid sequence identity with melanoma growth stimulatory activity (MGSA/gro). J Exp Med 1990;171:1091.
106. Schröder JM, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 1987;139:3474.
107. Walz A, Strieter RM, Schnyder S. Neutrophil-activating peptide ENA-78. Chemokines 1993:129-137.
108. Ludwig A, Petersen F, Zahn S, et al. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood 1997;90:4588-4597.
109. White JR, Lee JM, Young PR, et al. Identification of a potent, selective nonpeptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-10098.
110. Wolf M, Delgado MB, Jones SA, Dewald B, Clark-Lewis I, Baggiolini M. Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2. Eur J Immunol 1998;28:164-170.
111. Alam R, Stafford S, Forythe P, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442-3447.
112. Dahinden CA, Geiser T, Brunner T, et al. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 1994;179:751-756.
113. Kameyoshi Y, Dörschner A, Mallet AI, Christophers E, Schröder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587-592.
114. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489-1495.
115. Weber M, Uguccioni M, Ochsenberger B, Baggiolini M, dark-Lewis I, Dahinden CA. Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3. J Immunol 1995;154:4166-4172.
116. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998;160:1411-1418.
117. Youn BS, Zhang SM, Lee EK, et al. Molecular cloning of leukotactin-1: a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J Immunol 1997;159:5201-5205.
118. 81: two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood 1998;91:3118-3126.
119. Campbell JJ, Bowman EP, Murphy K, et al. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol 1998;141:1053-1059.
120. Kim CH, Pelus LM, White JR, Applebaum E, Johanson K, Broxmeyer HE. CK beta-11/ macrophage inflammatory protein-3 beta/ EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells, J Immunol 1998;160:2418-2424.
121. Beck LA, Dalke S, Leiferman KM, et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997;159:2902-2972.
122. Ben-Baruch A, Xu L, Young PR, Bengali K, Oppenheim JJ, Wang JM. Monocyte chemotactic protein-3 (MCP-3) interacts with multiple leukocyte receptors - C-C CKR1, a receptor for macrophage inflammatory protein-1a/RANTES, is also a functional receptor for MCP-3. J Biol Chem 1995;270:22123-22128.
123. Mackay CR. Chemokine receptors and T cell chemotaxis. J Exp Med 1996;184:799-802.
124. Ponath PD, Qin S, Post TW, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183:2437-2448.
125. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183:2349-2354.
126. Petering H, Hochstetter R, Kimmig D, Smolarski R, Kapp A, Eisner J. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol 1998;160:555-558.
127. Elsner J, Petering H, Hochstetter R, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997;27:2892-2898.
128. Tiffany HL, Alkhatib G, Combadiere C, Berger EA, Murphy PM. CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells. J Immunol 1998;160:1385-1392.
129. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171-2176.
130. White JR, Imburgia C, Dul E, et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997;62:667-675.
131. Elsner J, Petering H, Kluthe C, et al. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 1998;28 (in press).
132. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-456.
133. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-2007.
134. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (This) and This. J Exp Med 1998;187:129-134.
135. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746-754.
136. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-883.
137. 2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guaninc nucleotide-binding protein. Blood 1996;88:3195-3199.
138. Tenscher K, Metzner B, Hofmann C, Schopf E, Norgauer J. The monocyte chemotactic protein-4 induces oxygen radical production, actin reorganization, and CD11b up-regulation via a pertussis toxin-sensitive G-protein in human eosinophils. Biochem Biophys Res Commun 1997;140:32-35.
139. 2-terminal residues. J Exp Med 1995,-181:631-640.
140. 2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J Exp Med 1996;183:681-685.
141. Wells TNC, Power CA, Lusti-Narasimhan M, et al. Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996;59:53-60.
142. Baggiolini M, Moser B. Blocking chemokine receptors. J Exp Med 1997;186:1189-1191.
143. Proudfoot AE, Power CA, Hoogewerf AJ, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-2603.
144. Teixeira MM, Wells TN, Lukacs NW, et al. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 1997;100:1657-1666.
145. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
146. Mack M, Luckow B, Nelson PJ, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998;187:1215-1224.
147. Struyf S, De Meester I, Scharpe S, et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998;28:1262-1271.
148. Proost P, Struyf S, Couvreur M, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2 (6-76) as a natural chemokine inhibitor. J Immunol 1998;160:4034-4041.
149. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26-mediated cleavage. J Exp Med 1997;186:1865-1872.
150. Wells TN, Schwartz TW. Plagiarism of the host immune system: lessons about chemokine immunology from viruses. Curr Opin Biotechnol 1997;8:741-748.
151. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998;160:614-633.
152. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184.
153. Haskell MD, Moy JN, Gleich GJ, Thomas LL. Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Blood 1995;86:4627-4637.
154. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-4758.
155. Lim KG, Wan HC, Bozza PT, et al. Human eosinophils elaborate the lymphocyte chemoattractants - IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 1996;156:2566-2570.
156. Yousefi S, Hemmann S, Weber M, et al. IL-8 is expressed by human peripheral blood eosinophils - evidence for increased secretion in asthma. J Immunol 1995;154:5481-5490.
157. Ying S, Meng Q, Taborda Barata L, et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 1996;26:70-76.
158. Lacy P, Levi-Schaffer F, Mahmudi-Azer S, et al. Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon gamma. Blood 1998;91:2508-2516.
159. Levi-Schaffer F, Weg VB. Mast cells, eosinophils and fibrosis. Clin Exp Allergy 1997;27 Suppl 1:64-70.
160. Grewe M, Czech W, Morita A, et al. Human eosinophils produce biologically active IL-12: implications for the control of T-ccll responses in atopic dermatitis. J Immunol 1998 (in press).
161. Druilhe A, Cai Z, Haile S, Chouaib S, Pretolani M. Fas-mediated apoptosis in cultured human eosinophils. Blood 1996;87:2822-2830.
162. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995;86:1437-1443.
163. Simon HU. Molecular mechanisms of defective eosinophil apoptosis in diseases associated with eosinophilia. Int Arch Allergy Immunol 1997;113:206-208.
164. Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
165. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU. Requirement of Lyn and Syk tyrosine kinases for the prevention of apotosis by cytokines in human eosinophils. J Exp Med 1996;183:1407-1414.
166. Simon HU, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K. Anti-apoptotic signals of granulocyte-macrophagc colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27:3536-3539.
167. Hebestreit H, Dibbert B, Balatti I, et al. Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998;187:415-425.
168. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytcs. J Immunol 1996;156:4422-4428.